Skip to the content
Seraxislogo darklogo light
  • Home
  • Technology
  • Pipeline
  • About
    • Leadership
    • Press Releases
    • In the News
    • Publications & Presentations
    • Contact Us
Search
Seraxis
  • Home
  • Technology
  • Pipeline
  • About
    • Leadership
    • Press Releases
    • In the News
    • Publications & Presentations
    • Contact Us
HomePublication
Publication

The transcription factors ISL-1 and MAFA, but not NKX6-1 Characterize a Stem-cell Derived Population of Endocrine Pancreatic Cells Capable of Controlling blood Glucose in Rodent Models of Diabetes.

admin
December 31, 2023
Publication

Cell Replacement Therapy for Insulin-Dependent Diabetes: Maintaining Islet Architecture and Distribution After Graft.

admin
April 30, 2020
Publication

Generation and selection of pluripotent stem cells for robust differentiation to insulin-secreting cells capable of reversing diabetes in rodents.

admin
September 5, 2018

Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes

admin
October 15, 2024

ENDPOINTS NEWS: Maryland biotech gets green light for stem cell-derived therapy for diabetes, aiming to compete with Vertex

admin
October 15, 2024
Categories
In the news Presentation Press Release Publication
We believe in open projects
View more
Seraxis, Inc.

Seraxis, Inc | 20400 Century Blvd, Suite 150 | Germantown, MD 20874

Home

Technology

Publications & Presentations

Pipeline

About

Press Releases

Contact Us

© 2026 Seraxis, Inc. All Rights Reserved

Back to top Drag
w
  • Services
  • Careers
  • Contact Us